Panbela Therapeutics Pre-Paid Expenses 2020-2024 | PBLA

Panbela Therapeutics pre-paid expenses from 2020 to 2024. Pre-paid expenses can be defined as a current asset created by prepayment of costs and expenses for which the benefits will occur at a future date.

Panbela Therapeutics Pre-Paid Expenses 2020-2024 | PBLA

Panbela Therapeutics pre-paid expenses from 2020 to 2024. Pre-paid expenses can be defined as a current asset created by prepayment of costs and expenses for which the benefits will occur at a future date.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$141.5B
Gilead Sciences (GILD)$117.7B
Bristol Myers Squibb (BMY)$117.6B
Vertex Pharmaceuticals (VRTX)$105.8B
CSL (CSLLY)$85.8B
Regeneron Pharmaceuticals (REGN)$78.8B
GSK (GSK)$70.7B
Argenex SE (ARGX)$38.2B
Alnylam Pharmaceuticals (ALNY)$31.3B
BioNTech SE (BNTX)$27.3B
Biogen (BIIB)$21.8B
Illumina (ILMN)$21.4B
BeiGene (BGNE)$18B
Moderna (MRNA)$15.6B
Genmab (GMAB)$13.6B
Incyte (INCY)$13.4B
BioMarin Pharmaceutical (BMRN)$12.8B
Insmed (INSM)$12.6B
Sarepta Therapeutics (SRPT)$11.8B
Bio-Techne Corp (TECH)$11.6B
Vaxcyte (PCVX)$10.7B
Exact Sciences (EXAS)$10.6B
QIAGEN (QGEN)$10.3B
Swedish Orphan Biovitrum (BIOVF)$9.8B
Exelixis (EXEL)$9.7B
Bio-Rad Laboratories (BIO.B)$9.1B
Intra-Cellular Therapies (ITCI)$9.1B
Roivant Sciences (ROIV)$8.7B
Ascendis Pharma (ASND)$8.5B
Repligen (RGEN)$8.2B